Evogene (EVGN) Gross Margin (2012 - 2026)

Evogene (EVGN) posted Gross Margin of 61.08% for Q1 2026, up 109.74% sequentially from 627.39% in Q4 2025, and up 2582.0% YoY from 2.28% in Q1 2025.

Evogene (EVGN) Gross Margin (2012 - 2026) Analysis & Trends

Evogene has reported Gross Margin for 15 years, with the latest figure at 61.08% in Q1 2026.

Quarterly Gross Margin rose 2582.0% year-over-year to 61.08% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 46.8% (down 8923.0% YoY) and the FY2025 annual result came in at 6.25%, down 6358.0% from the prior year.
Gross Margin rose to 61.08% in Q1 2026 per EVGN's latest filing, from 627.39% in the prior quarter.
Over five years, Gross Margin peaked at 92.6% in Q1 2024 and troughed at 627.39% in Q4 2025.
A 5-year average of 11.69% and a median of 44.85% in 2022 frame the typical range for Gross Margin.
The sharpest annual moves came in 2024 and 2025: Gross Margin surged 4284 bps in 2024, then plunged 68254 bps in 2025.
Over 5 years, Gross Margin stood at 44.85% in 2022, then tumbled by 31 bps to 31.14% in 2023, then surged by 77 bps to 55.15% in 2024, then slumped by 1238 bps to 627.39% in 2025, then surged by 110 bps to 61.08% in 2026.
According to Business Quant data, Gross Margin over the past three periods registered 61.08%, 627.39%, and 49.68% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	91.59%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	90.43%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	76.90%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	63.27%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	84.20%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Evogene	4.38 Mn	4.38 Mn	204,000.00	61.08%

Download Data